In Q1 2025, J.P. Morgan’s biopharma and medtech deal reports—powered by DealForma—highlighted sustained investor interest with $6.7B in biopharma and $3.7B in medtech venture funding, alongside significant licensing and M&A activity, despite a cautious IPO market. Download their analysis
